


A Formal Synthesis of a Novel Immunosuppressant ISP-1 : Stereo-controlled Pd(O) Catalysed *cis*-Hydroxyamination of Carbohydrate derived Vinyl Epoxide

A V Rama Rao*, Mukund K Gurjar, T Rama Devi and K Ravi Kumar
Indian Institute of Chemical Technology, Hyderabad 500 007, India


Abstract: Described herein are the results leading to the synthesis of ISP-1 containing an unusual α,α -disubstituted amino acid and whose immunosuppressive activity only has recently been discovered.

The current level of interest in chiral α,α -disubstituted amino acids has been intensified because they (i) show enzyme inhibitory activities, (ii) influence structures of polypeptides incorporating them and (iii) form part structures of many bioactive natural products¹. For




instance the novel immunosuppressant ISP-1 (I), recently isolated² from the culture broth of *Isaria sinclairii* (Berkeley) sacc. (ATCC No. 24400), contained an unusual α,α -disubstituted amino acid framework. ISP-1 (myriocin or thermozyomicidin^{3,4}) is an attractive target because the newly discovered immunosuppressive activity was comparable to or slightly higher than clinically used cyclosporin A and secondly the structural features were rather simple as compared to other immunosuppressive agents, cyclosporin A or FK-506. In fact, ISP-1 has been converted into several analogues, many of which are currently undergoing clinical trials⁵.

At the methodological front, the critical Strecker type but modified reaction to generate α,α -disubstituted amino nitrile precursors has been employed by earlier workers^{6,7}, however, the diastereoselectivity was found extremely poor providing almost 1:1 mixture of isomers of the corresponding α,α -disubstituted amino acids. We, therefore, proposed to design an alternate but stereochemically controlled approach (retrosynthesis scheme 1) for the crucial precursor (compound type A) for which we chose carbohydrate as the starting material⁸ and relied upon Pd(O) catalysed *cis*-hydroxyamination reaction of chiral vinyl epoxide. Trost and coworkers⁹, with a variety of vinyl epoxides, have exemplified this reaction which occur with high degree of regioselectivity with retention of epoxide configuration. The stereochemical centers at C-3 and C-4 of *D*-glucose correlated with C-4 and C-3 of the target molecule I. However, the off-template stereoselectivity of the *cis*-hydroxyamination reaction (compound type B)



Scheme - 2



(a) TBS-Cl, Imid., DMF, RT, 4h; b) (COCl)₂, DMSO, Et₃N, CH₂Cl₂, -78°, 2h; c) CH₂=CH-MgBr, THF, RT, 1h; d) (i) Bu₃NF, THF, RT, 2h; ii) PPh₃, DEAD, C₆H₅CH₃, Δ, 5h; e) (i) NaI, Bu₃SnH, AIBN (cat), C₆H₆, Δ, 6h; ii) NaH, MeI, THF, RT, 5h; f) (i) Pd-C, H₂, MeOH, 1 atm, 3h; ii) NaH, BnBr, THF, 5h; g) 4-OMe-C₆H₄-NCO, Pd(PPh₃)₄, THF, (CH₃(CH₂)₃CHO)₂P, RT, 18h; h) i) O₃, CH₂Cl₂, NaBH₄; ii) NaH, BnBr, THF, 5h; i) CAN, CH₃CN-H₂O, RT, 6h; j) i) 5N NaOH, THF, Δ, 3-5h; ii) Bz₂O, MeOH, 24h; k) i) RuCl₃, NaIO₄, H₂O, CCl₄, CH₃CN, RT, 6h; ii) CH₂N₂, EtOEt, 1h; iii) Pd-C, H₂, MeOH, 35 psi, 24h; l) NH₃, MeOH, 30 min.; m) i) CH₃COOH, H₂O, 50°, 5h; ii) NaCNBH₃, THF, RT, 2h; n) Ref. 7.

on carbohydrate derived vinyl epoxide (interestingly containing many chiral centers, compound type C) would require special attention.

Compound **2** (readily obtainable¹⁰ from D-glucose) was mono-silylated (TBS-Cl, Imid. DMF) to give **3** which by Swern oxidation (DMSO, (COCl)₂, Et₃N, CH₂Cl₂ -78°) was transformed into the 5-ulose derivative (**4**). Treatment of **4** with vinylmagnesium bromide in THF gave **5**¹⁴ as an exclusive product (80%). The structure and the configuration at C-5 were confirmed by the following sequence of transformations leading to a known product¹¹. For example, **5** was subjected to desilylation (Bu₄NF, THF) and then to epoxidation reaction under the Mitsunobu conditions¹² (DEAD, TPP, C₆H₄CH₃, δ) to provide **6**. When **6** was heated under reflux with NaI, tributyltin hydride in refluxing benzene containing cat. AIBN¹³, the 6-deoxy product was isolated which on methylation (NaH, MeI, THF) gave **7**. Its subsequent hydrogenation (Pd-C, H₂, MeOH) and re-benzylation (NaH, BnBr, THF) afforded the known compound **8** ([α]_D -64°, lit.¹¹




Figure - A (9)

[α]_D -68°). Having established, during the above process, the absolute stereochemistry of the vinyl epoxide (**6**), we then considered the cis-hydroxyamination step. 4-Methoxyphenylisocyanate was the reagent of choice due to readily removable 4-methoxyphenyl group. Treatment of **6** with 4-methoxyphenylisocyanate in the presence of a catalytic amount of Pd (PPh₃)₄ and triisopropylphosphite in THF gave a single oxazolidinone derivative **9** (76%). Although, the ¹H-NMR spectrum revealed the gross structure of the product, the absolute stereochemical assignments were based on single crystal X-ray diffraction studies (Fig.A).

Compound **9** was subjected to successive ozonolysis (O₃, CH₂Cl₂) in situ reduction (NaBH₄) and benzylation (NaH, BnBr, THF). From the expected product **10**, 4-methoxyphenyl substituent was cleaved (CAN, CH₃CN-H₂O), to obtain **11**. Hydrolysis of the oxazolidinone ring with an alkali (5N NaOH, THF, δ) then gave the amino alcohol derivative which was selectively N-benzoylated [(Bz)₂O, MeOH] to provide **12**.

For the forthcoming conversion of CH₂OH → COOMe, **12** was oxidised (RuCl₃, NaIO₄, CCl₄, CH₃CN, H₂O) and esterified (CH₂N₂, EtOEt) to afford two products as judged by TLC. However, the mixture as such was hydrogenolysed (Pd-C, H₂, MeOH) and then chromatographed to provide **13a** and **13b** (1:3) (85%). Their structures were illustrated by the ¹H-NMR spectra. The resonances due to methylene protons were clearly apparent in both spectra of **13a** and **13b** as a AB quartet, but whereas the positions of all other ring proton resonances were comparable, that due to the methylene protons showed an upfield shift of 0.79 ppm in the benzoylated product (**13a**). The isolation of **13a** indicated that at Ru-oxidation stage, the primary O-benzylic group also underwent selective oxidation to generate O-benzoate, while the secondary O-benzyl remained unaffected. However, de-O-benzylation of **13a** (NH₃, MeOH) furnished **13b**. Cleavage of the isopropylidene group (CH₃COOH, H₂O, 50°) and reduction (NaCNBH₃, THF) provided **14**. All the stereochemical centers in **14** correlated with those present in the key intermediate **14a** except for the chiral center at C-5 which is anyway destroyed in the subsequent steps

to produce the aldehyde 15⁷. Compound 15 has already been converted into myriocin (ISP-1)⁷.

This communication describes the first stereocontrolled approach towards the biologically and medicinally valuable immunosuppressant ISP-1. We are now contemplating the applications of this approach to other α - β -disubstituted amino acids of biological significances.

References

1. a) Bey, P.; in *Enzyme Activated Irreversible Inhibitors*; Seiler, N.; Jung, M.J.; and Koch-Weser, J.; Eds. Elsevier Pub., Amsterdam, 1978; b) Bey, P.; MetCalf, B.W.; Jung, M.J.; Forzard, J.; Koch-Weser, J.; in *Strategy in Drug Research*, Keveling-Buisman, J.A.; Elsevier Pub., Amsterdam, 1982; c) Tendler, S.J.B.; Threadgill, M.D.; Tisdase, M.J.; *J. Chem. Soc. Perkin. Trans. 1*, 1987, 2617; d) Williams, R.M.; *Synthesis of Optically active α -amino acids*, Pergamon Press, Oxford, 1989.
2. Fujita, T.; Inoue, K.; Yamamoto, S.; 17th IUPAC International Symposium on the Chemistry of Natural Products, New Delhi, 1990.
3. Kluepfel, D.; Bagli, J.; Baker, H.; Charest, M.-P.; Kudelski, A.; Sehgal, S.N.; and Vezina, C.; *J. Antibiotic*, 1972, 25 109.
4. a) Craveri, R.; Manachini, P.L.; and Aragozzini, F.; *Experientia*, 1972, 28, 867; b) Kuo, C.H.; and Wendler, N.L.; *Tetrahedron Lett.*, 1978, 3, 211.
5. *Drug Data Report*, 1991, 13, 506 (Article No. 169735).
6. Just, G.; and Payette, D.R.; *Tetrahedron Lett.*, 1980, 21, 3219.
7. Banfi, L.; Beretta, M.G.; Colombo, L.; Gennari, C.; Scolastico, C.; *J. Chem. Soc. Perkin Trans. 1*, 1983, 1613.
8. Hanessian, S.; *Total Synthesis of Natural Products. The 'Chiron' Approach*. Pergamon Press, London, 1983.
9. a) Trost, B.M.; Sudhakar, A.R.; *J. Am. Chem. Soc.* 1987, 109, 3792; b) idem. *J. Am. Chem. Soc.* 1988, 110, 7933; c) Trost, B.M.; Hurnaus, R. *Tetrahedron Lett.*, 1989, 30, 3893.
10. Anderson, R.C.; and Fraser-Reid, B.; *J. Org. Chem.*, 1985, 50, 4781 and references therein.
11. Kinoshita, M.; and Mori, Y.; *Bull. Chem. Soc. Japan*, 1985, 58, 3298.
12. Mitsunobu, O.; *Synthesis* 1981, 1.
13. Bonini, C.; and Di Fabio, R.; *Tetrahedron Lett.*, 1988, 29, 819.
14. Physical data of some selected compounds:
 Compound 5: ¹H-NMR (CDCl₃, 200 MHz): δ 0.02 (s, 6H, Me₂Si), 0.87 (s, 9H, (CH₃)₃CSi), 1.34, 1.48 (2s, 6H, Me₂C), 3.44 (d, 1H, J 8.0 Hz, H-6a), 3.59 (d, 1H, J 8.0 Hz, H-6b), 4.12 (d, 1H, J 3.4 Hz, H-3), 4.29 (d, 1H, J 3.4, H-4), 4.48, 4.68 (ABq, 2H, PhCH₂), 4.59 (d, 1H, J 4.2 Hz, H-2), 5.17 (dd, 1H, J 1.0, 10.7 Hz, 1/2 CH₂= [cis]), 5.44 (dd, 1H, J 1.0, 17.0 Hz, 1/2 CH₂= [trans]), 5.97 (d, 1H, J 4.2 Hz, H-1), 6.0 (m, 1H, CH=), 7.30 (s, 5H, Ph). $[\alpha]_D^{25}$ -25° (c 1.3, CHCl₃).
 Compound 6: ¹H-NMR (CDCl₃, 200 MHz): δ 1.34-1.50 (2s, 6H, Me₂C), 2.74 (d, 1H, J 8.0 Hz, H-6a), 3.18 (d, 1H, J 8.0 Hz, H-6b), 4.08 (d, 1H, J 3.6 Hz, H-3), 4.32 (d, 1H, J 3.6 Hz, H-4), 4.58 (ABq, 2H, PhCH₂), 4.64 (d, 1H, J 4.0 Hz, H-2), 5.18 (dd, 1H, J 1.0, 12.0 Hz, 1/2 CH₂= [cis]), 5.38 (dd, 1H, J 1.0, 18.0 Hz, 1/2 CH₂= [trans]), 5.94 (d, 1H, J 4.0 Hz, H-1), 6.05 (m, 1H, CH=), 7.30 (m, 5H, Ph). $[\alpha]_D^{25}$ -60° (c 1.1, CHCl₃).
 Compound 7: ¹H-NMR (CDCl₃, 200 MHz): δ 1.32, 1.46, 1.50 (3s, 9H, Me₂C+CH₃), 3.20 (s, 3H, OMe), 3.88 (d, 1H, J 3.6 Hz, H-3), 4.06 (d, 1H, J 3.6 Hz, H-4), 4.44, 4.62 (ABq, 2H, PhCH₂), 4.54 (d, 1H, J 4.0 Hz, H-2), 5.15-5.41 (m, 2H, CH=), 5.84 (dd, 1H, J 12.0, 18.0 Hz, CH=), 5.96 (d, 1H, J 4.0 Hz, H-1), 7.30 (s, 5H, Ph).
 Compound 9: ¹H NMR (CDCl₃, 200 MHz): δ 1.30, 1.35 (2s, 6H, Me₂C), 3.76 (bs, 4H, OMe+H-6a), 4.14 (d, 1H, J 3.5 Hz, H-3), 4.26 (d, 1H, J 7.0 Hz, H-6b), 4.30 (d, 1H, J 3.5 Hz, H-4), 4.52, 4.73 (ABq, 2H, PhCH₂), 4.54 (d, 1H, J 4.2 Hz, H-2), 5.30 (dd, 1H, J 11.9, 17.8 Hz, CH₂=), 5.72 (dd, 1H, J 11.9, 17.8 Hz), 6.00 (d, 1H, J 4.2 Hz, H-1), 6.83 (d, 2H, Ar), 7.3 (m, 7H, Ar). Mass spectrum: m/z 467 (M⁺). $[\alpha]_D^{25}$ -64° (c 1.3, CHCl₃).
 Compound 13b: ¹H NMR (CDCl₃, 200 MHz): δ 1.43, 1.52 (2s, 6H, Me₂C), 4.06 (ABq, 2H, J 12.7 Hz, CH₂), 4.88 (d, 1H, J 4.0 Hz, H-5), 5.09 (d, 1H, J 3.2 Hz, H-3), 5.31 (d, 1H, J 3.2 Hz, H-4), 5.95 (d, 1H, J 4.0 Hz, H-6), 6.70 (s, 1H, NH), 7.4-7.9 (m, 5H, Ph). $[\alpha]_D^{25}$ +19° (c 0.3, CHCl₃).